

Paolo Tarantino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9707501/publications.pdf>

Version: 2024-02-01

51
papers

1,716
citations

394421

19
h-index

330143

37
g-index

51
all docs

51
docs citations

51
times ranked

1630
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	329.8	132
2	Aiming at a Tailored Cure for <i>ERBB2</i> -Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 629.	7.1	18
3	Evolution of low HER2 expression between early and advanced-stage breast cancer. <i>European Journal of Cancer</i> , 2022, 163, 35-43.	2.8	88
4	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. <i>Annals of Oncology</i> , 2022, 33, 234-238.	1.2	11
5	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.	5.2	67
6	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	5.2	8
7	Bystander effect of antibody-drug conjugates: fact or fiction?. <i>Current Oncology Reports</i> , 2022, 24, 809-817.	4.0	35
8	Harmonizing PD-L1 testing in metastatic triple negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 345-348.	3.1	10
9	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153.	2.4	5
10	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 106, 102395.	7.7	60
11	Aiming for the Cure in <i>ERBB2</i> -Positive Metastatic Breast Cancer—Should We Go “All In”? Reply. <i>JAMA Oncology</i> , 2022, 8, 1221.	7.1	8
12	Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3063-3063.	1.6	0
13	Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. <i>Cancers</i> , 2022, 14, 3193.	3.7	9
14	Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 855-874.	4.1	2
15	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188487.	7.4	16
16	Margetuximab for the treatment of HER2-positive metastatic breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 127-133.	3.1	21
17	Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2021, 92, 102133.	7.7	4
18	New anti-HER2 agents for brain metastasis: histology-agnostic weapons?. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 879-881.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 885-886.	2.5	3
20	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169.	7.7	14
21	Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103223.	4.4	52
22	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , 2021, 154, 151-160.	2.0	25
23	SARS-CoV-2 vaccines for cancer patients: a call to action. <i>European Journal of Cancer</i> , 2021, 148, 316-327.	2.8	55
24	Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. <i>Cancer Treatment Reviews</i> , 2021, 97, 102205.	7.7	21
25	Mastering the Use of Novel Anti-HER2 Treatment Options. <i>JCO Oncology Practice</i> , 2021, 17, 605-606.	2.9	6
26	Anthracyclines for Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3541-3545.	1.6	6
27	Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. <i>Pharmaceuticals</i> , 2021, 14, 884.	3.8	17
28	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021, 99, 102253.	7.7	26
29	Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. <i>Expert Opinion on Investigational Drugs</i> , 2021, , 1-15.	4.1	8
30	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. <i>JAMA Oncology</i> , 2021, 7, 1873.	7.1	66
31	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 5829.	3.7	8
32	Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. <i>European Journal of Cancer</i> , 2020, 139, 92-98.	2.8	12
33	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. , 2020, 8, e001154.		13
34	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Nonâ€“Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa064.	2.9	4
35	Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1009-1024.	3.1	23
36	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962.	1.6	353

#	ARTICLE	IF	CITATIONS
37	Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)â€related disease pandemic. <i>European Journal of Cancer</i> , 2020, 132, 8-10.	2.8	12
38	Autoimmune Liver Diseases and Antiphospholipid Antibodies Positivity: a Meta-analysis of Literature Studies. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 25-34.	0.9	24
39	Defining the immunogram of breast cancer: a focus on clinical trials. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 383-385.	3.1	14
40	RADIOFREQUENCY ABLATION FOR LIVER METASTASES IN THE TREATMENT OF ADVANCED BREAST CANCER. <i>Breast</i> , 2019, 48, S74.	2.2	0
41	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 171-182.	4.4	93
42	Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1168, 9-30.	1.6	114
43	Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. , 2019, 2, 43-52.		4
44	Electrochemotherapy of cholangiocellular carcinoma at hepatic hilum: A feasibility study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1603-1609.	1.0	28
45	Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. <i>World Journal of Gastroenterology</i> , 2017, 23, 906.	3.3	51
46	The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 221, 746-754.	1.7	60
47	Cardiovascular risk markers in patients with primary aldosteronism: A systematic review and meta-analysis of literature studies. <i>International Journal of Cardiology</i> , 2016, 208, 46-55.	1.7	30
48	Percutaneous electrochemotherapy of malignant main portal veins thrombosis: a prospective case series.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15586-e15586.	1.6	0
49	Viral hepatitis and anti-phospholipid antibodies positivity: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2015, 47, 478-487.	0.9	25
50	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.8	1
51	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 0, , .	7.1	51